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ABSTRACT  
The present study was undertaken to synthesize, characterize  and evaluate the anticancer activity of  new derivatives of 
hydroxamate –based HDACi  having S-subistituted-5-amino1,3,4thadiazole as a cap linking moiety ,with suitable aliphatic 
linker.The structures and purity of the targeted compounds were confirmed by TLC , FTIR ,H-NMR and mass 
spectroscopy and their anticancer activity were evaluated by comparative cytotoxic study , Using HeLa nuclear extract and 
normal embryonic fibroblasts cell lines. All the synthesized compounds shows good anticancer activity, represented by 
their high rate of growth inhibition on Hela cell line and low cytotoxic effect on normal cell line . Compound (VAb) show the 
best safety index(SI) that represented by its  selective cytotoxic activity on HeLa cell line with  low cytotoxic effect on 
normal embryonic cell line. 
KEYWORDS:HDACis ,5-amino 1,3,4thiadiazole-2-thiol  . new CAP groups. 
1.INTRODUCTION  
Epigenetic regulation of specific gene expression is mediated by several mechanisms, among which is post-translational 
acetylation of the side-chain amino groups of specific histone lysine residues
.(1).
 The acetylation status of histones is 
modulated by histone acetyltransferases (HAT) and histone deacetylases (HDAC).)HAT) is generally considered as a 
transcriptional activator, and HDAC is considered as a transcriptional inhibitor
(2).
 Eighteen mammalian HDACs have been 
identified and categorized into four structural and functionally distinct classes
(3).
 
Many recent studies have shown that inhibition of HDAC elicits anticancer effects in several lines of tumor cells by 
inhibiting cell growth and inducing apoptosis
(4).
Natural and synthetic HDAC inhibitors have been studied extensively , and 
suberoylanilidehydroxamic acid (SAHA)has been approved by the FDA for once-daily oral treatment of advanced 
cutaneous T-cell lymphoma (CTCL), 
(5(.
 
. Most of the HDAC inhibitors have three common features: cap group, zinc binding group (ZBG) and hydrophobic 
spacer
(6). 
The hydroxamic acid moiety has been widely used as zinc binding group., the cap group is by far the most 
common moiety to modify in order to obtain isoform selectivity
(7).
 The hydrophobic linker is also relatively versatile, 
although it often takes the form of a lengthy aliphatic chain. The zinc-binding group is a requirement for HDAC inhibition 
and takes the form of hydroxamic acids
(8)
 .Inhibition of HDAC activity has emerged as a promising option  for reversing the 
abnormal epigenetic status that  associated with cancer as well as other chronic diseases, however,  Most HDACi are 
global, non-selective inhibitors of various HDAC isoform, so they does not differentiate the relevant HDACs that regulate 
proliferation, apoptosis or angiogenesis
(9)
. In addition, low oral bioavailability, short half-life time, bone marrow toxicity, and 
cardio toxicity are limiting the clinical use of some current HDACi
(10)
. Therefore, there is considerable interest in 
developing compounds with  great selectivity towards individual family members of HDACs, and with improved 
pharmacokinetic and pharmacodynamics profiles
(11).
 
    The present study was undertaken to synthesize and evaluate the anticancer activity of  new hydroxamate –based 
HDACi  having S-subistituted-1-3,4thadiazole derivatives  ,with suitable aliphatic linker with hope of obtaining inhibitors  
which more selective , potent and  with improved pharmacokinetic properties All the new compounds were characterized 
by elemental and spectral analysis and screened for their invitro, antitumor activity 
2.MATERIALS AND METHODS 
EXPERIMENTAL 
All the newly synthesized compounds gave good to moderate yields and their structures  were ascertained by thin layer 
chromatography (TLC) on silica gel G (Merck) coated plates by using  different solvent system. The visualization of ( TLC) 
spots was done by using Iodine chamber and UV lamp. The chemicals and solvents were purchased from Fluka, BDH, 
and Thomas Baker companies. Melting points were determined on Thomas Hooverelectric melting points apparatus and 
are uncorrected. FT-IR spectra (KBr) were recorded on Shimadzu  FT-R-8400S spectrophotometer and 
1
HNMR spectra 
measured with400MHz,Avance III 400-Bruker, using tetramethylsilane as an internal standard ..The percentage of 
carbon,hydrogen and nitrogen were obtained using a CHN analyzer ( Euro EA3000 elemental analyzer. 
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GENERAL METHODS  
The target compounds were synthesized by the following steps 
2.1Synthesis of 5-amino-1, 3, 4-thiadiazole-2-thiol, compound (1)(12) 
Thiosemicarbazide (9.11 g, 100 mmol), was dissolved in absolute ethanol (75 ml), anhydrous sodium carbonate (5.3 g, 50 
mmol), and carbon disulfide (6 ml, 100 mmol) were then added and the reaction mixture was refluxed with stirring for five 
hours. The reaction mixture then allows cooling at room temperature, then filtered. The filtrate was evaporated to dryness 
under vacuum, and the residue was dissolved in distilled water (200 ml), and acidified to pH 6 with 2 N, HCl to give 
greenish-yellow precipitate. The crude product was filtered, washed excessively with D.W and crystallized from hot water 
.to give compound 1 as greenish-yellow crystals. 
yellow powder , Yield  57%; m.p. 130°C ; IR (ʋ= cm-1,KBr):3396, 3277 (Asym. And sym. Str. of NH2 3091(NH 
str.)2773(SH str,)1600(NH bending) 1533 and 1496(C=N str.)1363(C=S str.)746(NH2 wagging). 
2.2General procedure for synthesis of compounds (2a-f)(13) 
A stirred solution that containing 0.028mole (3 ml benzylamine ,2.6 g 2-aminopyridine , 3.88g p-nitroaniline ,3.61 g p-
chloroaniline ,4.94 g p-bromoaniline ,3.5 g p-methoxyaniline )  in dry benzene(30 ml),TEA (4 ml, 0.029 mole ) was added 
drop wise, and the solution was cooled to 0 
o
C in ice bath,(2.147 ml ,0.028 mole) of CAC in 10 ml of dry benzene was 
added drop wise over a period 30 minute .The resulted mixture was stirred at room temperature for 2-4hr and reflexed for 
1-3 hr. then the solvent was evaporated under vacuum and the residue was washed twice with 15 of cold 5% potassium 
carbonate solution, and D.W successively  filtered , dried  and the obtained  powder was  recrystallized from ethanol 
Synthesis of compound N-benzyl-2-chloroacetamide, compound (2a). 
white powder , Yield  87%; m.p. 94-95°C ;FT IR (ʋ= cm-1,KBr):3278 (NH str.) , 30062and 3005(Ar-H str.), 2947 , 2877 
(Asym.and sym. Str. of  CH2), 1650 (C=O  str.amide), 1550(NH bending), 1427,1480(C=C str.) 
Synthesis of 2-chloro-N-(pyridin-2-yl)acetamide, compound (2b). 
Gray  powder , Yield  85%; m.p. 121-124°C; FT IR (ʋ= cm-1,KBr):3251 (NH str.) ,3078 (Ar-H str.), 2947 , 2870(Asym.and 
sym. Str. of CH2), 1681 (C=O str.amide ),1581(C=N str.),1543(NHbending )1462,1438(C=C str.) 
Synthesis of 2-chloro-N-(4-nitrophenyl)acetamide, compound (2c). 
yellow  powder , Yield  70%; m.p. 182-185°C;FT IR (ʋ= cm-1,KBr):3228 (NH str.) , 3107 ,3070 (Ar-H str.), 2941 , 2829 
(Asym.and sym. Str. of CH2), 1685 (C=O str.amide ),1624(NO2 str.),1599(NH bending ) 1568,1408 (C=C str.) 
Synthesis2-chloro-N-(4-chlorophenyl)acetamide,compound( 2d). 
Brawn powder , Yield  78%; m.p. 175-177°C;FT IR (ʋ= cm-1,KBr):3282 (NH str.) , 3101  (Ar-H str.), 2935 , 2829 
(Asym.and sym. Str. of CH2), 1660 (C=O str.amide ),1591(NH bending ) 1539,1491 (C=C str.) 
Synthesis of N-(4-bromophenyl)-2-chloroacetamide,compound (2e) 
Brawn powder , Yield  72%; m.p. 172-173°C;FT IR (ʋ= cm-1,KBr):3263 (NH str.) ,3078 , 3101  (Ar-H str.), 2953 , 
2885(Asym.and sym. Str. of CH2), 1670 (C=O str.amide ),1608(NH bending ) 1548,1459(C=C str.) 
Synthesisof2-chloro-N(4-methoxyphenyl)acetamide, compound (2f). 
Gray crystals , Yield  81%; m.p. 119-120; FT IR (ʋ= cm-1,KBr):3294 (NH str.) ,3072 , 3009  (Ar-H str.), 2956 , 2835 
(Asym.and sym. Str. of CH2), 1670 (C=O str.amide ),1606(NH bending ) 1550,1462(C=C str.) 
2.3 General procedure for synthesis of compounds (3a-g).(14). 
To a suspension of compound 1 (2 gm , 0.015 mole) in 30 ml of D.W placed in a suitable flask ,TEA (2.123 ml , 0.017 
mole) was added gradually at room temperature with continuous stirring, the resulted pale – yellow solution was filtered to 
remove the remaining insoluble starting material, then 0.013 mole of (benzyl chloride 1.5 ml ;2a,2.38g ; 2b ,2.21 g ;2c 
,2.78 g ;2d , 2.65 g ;2e ,1.8g ;2f ,2.6g ) was added In several divided portions  to the clear yellowish filtrate over a period of 
20-30 minute. Stirring was continued at room temperature for 3 hrs ,the progression of the reaction was followed by TLC. 
The resulted precipitate was filtered , washed with 20 ml of D.W several times ,dried and recrystallized from aqueous 
ethanol. 
Synthesis of 5-(benzylthio)-1,3,4-thiadiazol-2-amine, (3a) 
white crystals , Yield  92%; m.p. 113-116; FT IR (ʋ= cm-1,KBr):  3294,3107  (NH2str.) , 2955 , 2835 (Asym.and sym. Str. 
of CH2), 1616 (C=O str.amide ),1518(NH bending ) 1452,1423(C=N str.), 1375(CH2 bending). 
Synthesis of 2-(5-amino-1,3,4-thiadiazol-2-ylthio)-N benzylacetamide (3b) 
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white crystals , Yield  88%; m.p. 161-163;FT IR (ʋ= cm-1,KBr):  3394 and  331 (NH2 str.),3118(NH str.), 3082(Ar-H str.) , 
2931 , 2900 (Asym.and sym. Str. of CH2), 1651 (C=O str.amide ),1597 (NH bending ) 1524(C=N str.). 
Synthesisof2-(5-amino-1,3,4-thiadiazol-2-ylthio)-N-(pyridin-2-yl)acetamide, (3c). 
Khaki crystals , Yield  83%; m.p. 123-126;FT IR (ʋ= cm-1,KBr):  3358 and 3275(NH2 str.),3167(NH str.), 3095, 3005 (Ar-H 
str.) , 2970 , 2837 (Asym.and sym. Str. of CH2), 1676 (C=O str.amide ),1608 (NH bending ) 1583(C=N str.). 
Synthesisof2-(5-amino-1,3,4-thiadiazol-2-ylthio)-N-(4-nitrophenyl)acetamide, (3d). 
Yellow  crystals , Yield  81%; m.p. 155-157;FT IR (ʋ= cm-1,KBr):  3338 and 3231 (NH2 str.), 3172  (NH str.), 3111 (Ar-H 
str.) , 2939 , 2837 (Asym.and sym. Str. of CH2), 1684 (C=O str.amide ),1625 (NH bending ) 1570(C=N str.), 
Synthesis of 2-(5-amino-1,3,4-thiadiazol-2-ylthio)-N-(4-chlorophenyl)acetamide,  (3e). 
white crystals , Yield  84%; m.p. 144-147;FT IR (ʋ= cm-1,KBr):  3285 and 3199 (NH2 str.), 3132  (NH str.), 3084 ,3005 
(Ar-H str.) , 2953 , 2889 (Asym.and sym. Str. of CH2), 1670 (C=O str.amide ),1614 (NH bending ) 1597 (C=N str.). 
Synthesisof2-(5-amino-1,3,4-thiadiazol-2-ylthio)-N-(4-bromophenyl)acetamide (3f). 
white crystals , Yield  83%; m.p. 161-164;FT IR (ʋ= cm-1,KBr):  3300 ,3197 (NH2 str.), 3163  (NH str.), 3020 (Ar-H str.) , 
2875 (Asym.and sym. Str. of CH2), 1662 (C=O str.amide ),1618 (NH bending ) 1565 (C=N str.). 
Synthesisof2-(5-amino-1,3,4-thiadiazol-2-ylthio)-N-(4methoxyphenyl)acetamide, (3g). 
white crystals , Yield  83%; m.p. 105-107;FT IR (ʋ= cm-1,KBr):  3337 3275 (NH2 str.), 3136  (NH str.), 3070 (Ar-H str.) , 
2949 , 2837 (Asym.and sym. Str. of CH2), 1653 (C=O str.amide ), 1608 (NH bending ) 1541 (C=N str.). 
2.4General procedure for synthesis of compounds (4a-g)(15). 
Adipic acid monoethyl ester (4 gm , 0.022 mole ) was placed in a dry-100 ml two-necked flask connected with a dropping 
funnel and reflex condenser , Thionyl chloride (3.26 ml , 0.045 mole ) was added drop wise through the dropping funnel at 
room temperature  over a period of 30 minute with gentle stirring . Stirring was continued after completion of addition for 
additional 1 hr till the evolution of gases was stopped . The  solution was heated under reflex at 40 – 45 oC for 4 hrs and 
the excess thionyl chloride was removed under reduced pressure. The clear  liquid was dissolved without further 
purification  in 5 ml of dry DMF and added drop wise with stirring to an ice- cooled at 0 
o
C mixture of TEA (4.2ml , 0.03 
mole ) and 0.022mole of compounds 3a-g ( 3a ,4.9 g ;3b ,6.08g ;3c,5.8 g ;3d, 6.2 g; 3e,6.6 g; 3f , 7.5 g ; 3g ,6.6 g ) in 25 
ml of dry DMF. The resulted suspension was stirred at room temperature for 4 hrs and reflexed for additional 2 hrs. the 
solvent was evaporated, the residue was washed with cooled solution (3×20 ml) of 5 % HCl ,5 % sodium bicarbonate and 
D.W successively. The product was filtered ,collected ,dried and recrystallized from aqueous ethanol. . 
Synthesis of ethyl 6-(5-(benzylthio)-1,3,4-thiadiazol-2-ylamino)-6-oxohexanoate (4a). 
white crystals , Yield  74%; m.p. 90-93;FT IR (ʋ= cm-1,KBr):  3273 (NH str. of  sec .amide ), 3157  (NH str.), 3053 (Ar-H 
str.) , 2931 and 2870 (Asym.and sym. Str. of CH2), 1733(C=O str. of ester),1691(C=O str.amide ), 1651(NH bending ) 
1558 (C=N str.). 
Synthesisofethyl6-(5-(2-(benzylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2 ylamino)-6-
oxohexanoate(4b). 
white crystals , Yield  76%; m.p. 111-113;FT IR (ʋ= cm-1,KBr):  3325 (NH str. of  sec .amide ), 3163  (NH str.), 3034 (Ar-H 




white crystals , Yield  65%; m.p. 104-106;FT IR (ʋ= cm-1,KBr):  3172 (NH str. of  sec .amide ), 3122  (NH str.), 3032 (Ar-H 
str.) , 2978 ,2873 (Asym.and sym. Str. of CH2), 1734 (C=O str. of ester), 1691 (C=O str.amide ), 1575 (NH bending ) 1550 
(C=N str.). 
Synthesis of ethyl 6-(5-(2-(4-nitrophenylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-ylamino)-6-
oxohexanoate,(4d). 
yellow crystals , Yield  64%; m.p. 121-124;FT IR (ʋ= cm-1,KBr):  3266 (NH str. of  sec .amide ), 3161  (NH str.), 3109 (Ar-
H str.) , 2941 and 2873 (Asym.and sym. Str. of CH2), 1728 (C=O str. of ester), 1693 (C=O str.amide ), 1618 (NH bending ) 
1597 (C=N str.). 
Synthesis of ethyl 6-(5-(2-(4-chlorophenylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-ylamino)-6-
oxohexanoate, .  (4e). 
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white crystals , Yield  69%; m.p. 117-119;FT IR (ʋ= cm-1,KBr):  3265 (NH str. of  sec .amide ), 3132  (NH str.), 3084 (Ar-
H str.) , 2939 and 2844(Asym.and sym. Str. of CH2), 1732 (C=O str. of ester), 1693 (C=O str.amide ), 1668 (NH bending ) 
1668 (C=N str.). 
Synthesis of ethyl 6-(5-(2-(4-bromophenylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-ylamino)-6-
oxohexanoate, (4f). 
white crystals , Yield  66%; m.p. 87-91;FT IR (ʋ= cm-1,KBr):  3388 (NH str. of  sec .amide ), 3132  (NH str.), 3084 (Ar-H 
str.) , 2938 , 2875 (Asym.and sym. Str. of CH2), 1732 (C=O str. of ester), 1691 (C=O str.amide ), 1654 (NH bending ) 
1598 (C=N str.). 
Synthesis of ethyl 6-(5-(2-(4-methoxyphenylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-ylamino)-6-
oxohexanoate,  (4g). 
white crystals , Yield  58%; m.p. 72-74;FT IR (ʋ= cm-1,KBr):  3308 (NH str. of  sec .amide ), 3140  (NH str.), 3051 (Ar-H 
str.) , 2931 , 2833 (Asym.and sym. Str. of CH2), 1718 (C=O str. of ester), 1691 (C=O str.amide ), 1656 (NH bending ) 
1602 (C=N str.). 
2.5 General procedure for synthesis of compounds (5a-g)(16). 
A stirred solution of compounds 4a-g (0.0013 mole) (4a 0.5g , 4b,0.57g ;4c, 0.576g ;4d,0.65 g ;4e, 0.6g ; 4f,0.7 g 
;4g,0.58g) in dry 1:1 THF- methanol (15 ml) was cooled to 0
o
Cin ice-bath, and aqueous hydroxylamine  50 % (0.85 ml , 
0.013 mole, 10 equivalent ) was added followed by immediate addition of 3-6 mg of KCN . The mixture was allowed to 
warm to room temperature and stirred for 24-32hrs .Then, to the resulted yellow mixture , sodium hydroxide 10 equivalent  
was added and stirring continued for additional 1 hr. The solvent was removed under reduced pressure, and the obtained 
solid was dissolved in 15 ml of D.W ,filtered, and the clear filtrate was cooled and acidified with 0.1 N aqueous solution of  
HCl to pH 7. The resulted precipitate was filtered ,dried and recrystallized from methanol: n- hexane. 
SynthesisofN1-(5-(benzylthio)-1,3,4-thiadiazol-2-yl)-N6hydroxyadipamide,compound (5a). 
white crystals , Yield  72%; m.p. 81-83;FT IR (ʋ= cm-1,KBr):  3335 (OH str.), 3252  (NH str.) , 2924 (Asym.and sym. Str. 
of CH2), 1606 (C=O str. of amide,  1555 (C=N str.).
1
HNMR(400MHz),(DMSO-d6,δppm):12.1(s,1H,-OH),11.7(s,1H,CO-
NH), 11.3(s,1H,OH-NH), 7-8. (m,5H,Ar-H),4.4 (s, 2H,CH2-S),3.7(t,4H,CH2-CO) 2.8(t,4H,-CH2-) ; Elemental analysis Calcd. 
for C15H18N4O3S2: C, 49.16; H, 4.95; N, 15.29.Found: C, 49.55; H,4.656.33; N, 12.56.,N,14.05.                                                                
Synthesis of N1-(5-(2-(benzylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-yl)-N6-hydroxyadipamide, 
(5b). 
white crystals , Yield  60%; m.p. 122-124;FT IR (ʋ= cm-1,KBr):  3292 (OH str.), 3252  (NH str.) , 2929 , 2871 (Asym.and 
sym. Str. of CH2), 1692 (C=O str. of amide),  1643(amide II band ),1551 (C=N str.).
 1
HNMR(400MHz),(DMSO-
d6,δppm):12.4(s,1H,-OH),12.(s,1H,CO-NH), 11.5(s,1H,OH-NH),11.2(t,1H,CO-NH), 7-8. (m,5H,Ar-H),4.9(s,2H,CH2-S),4.1 
(s, 2H,CH2-Ar),3.4(t,4H,CH2-CO) 2.2(t,4H,-CH2-);Elemental analysis Calcd. for C17H21N5O4S2 : C, 48.21; H, 5.00; N, 16.54. 
Found: C, 49.07; H, 4.66; N,16.87 .                                                             
 SynthesisofN1-hydroxy-N6-(5-(2-oxo-2-(pyridin-2-ylamino)ethylthio)-1,3,4-thiadiazol-2-
yl)adipamide,(5c). 
white crystals , Yield  66%; m.p. 132-135;FT IR (ʋ= cm-1,KBr):  3280 (OH str.), 3252  (NH str.) ,3086(Ar-H str.) 2979 and 
2874 (Asym.and sym. Str. of CH2), 1697 (C=O str. of amide),  1573 (C=N str.). 
1
HNMR(400MHz),(DMSO-d6,δppm):11.9(s,1H,-OH),11.8 (s,1H,CO-NH-Ar), 11.4(s,1H,CO-NH),11 (s,1H,OH-NH), 7-8. 
(m,4H,Ar-H),4.1(s,2H,CH2-S),3.8 (t, 2H,CH2-CO),2.7(t,4H,-CH2-) ; -);Elemental analysis Calcd. for C15H18N6O4S : C, 43.89; 
H, 4.42; N, 20.47. Found: C, 43.22; H, 4.23; N, 20.78.                                                                 
Synthesis of N1-hydroxy-N6-(5-(2-(4-nitrophenylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-
yl)adipamide,(5d). 
white crystals , Yield  59%; m.p. 150-153;FT IR (ʋ= cm-1,KBr): 3241 (OH str.), 3165  (NH str.) , 3061 (Ar-H str.) 2951 and 
2873 (Asym.and sym. Str. of CH2), 1693 (C=O str. of amide), 1619 (C=N str.). 
1
HNMR(400MHz),(DMSO-d6,δppm):12.1(s,1H,-OH),11.7 (s,1H,CO-NH-Ar), 11.1(s,1H,CO-NH),10.9 (s,1H,OH-NH), 7-8. 
(m,4H,Ar-H),4.3(s,2H,CH2-S),3.6 (t, 2H,CH2-CO),2.4(t,4H,-CH2-) ;Elemental analysis Calcd for C16H18N6O6SC, 42.28; H, 
3.99; N, 18.49. Found: C, 41.60; H, 3.08; N, 17.88. 
Synthesis of N1-(5-(2-(4-chlorophenylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-yl)-N6-
hydroxyadipamide,(5e). 
white crystals , Yield  46%; m.p. 147-150;FT IR (ʋ= cm-1,KBr): 3209 (OH str.), 3132  (NH str.) , 3084 (Ar-H str.) 2939 and 
2880 (Asym.and sym. Str. of CH2), 1685 (C=O str. of amide), 1616 (C=N str.). 
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1
HNMR(400MHz),(DMSO-d6,δppm):12.4(s,1H,-OH),11.7 (s,1H,CO-NH-Ar), 11.3(s,1H,CO-NH),11.1 (s,1H,OH-NH), 7-8. 
(m,4H,Ar-H),4 (s,2H,CH2-S),3.4 (t, 2H,CH2-CO),2.4(t,4H,-CH2-) ; Elemental analysis Calcd for C16H18ClN5O4S2:C, 43.29; 
H, 4.09; N, 15.78. Found: C, 44.07; H, 4.18; N, 15.44 
Synthesis of N1-(5-(2-(4-bromophenylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-yl)-N6-
hydroxyadipamide,compound (5f). 
white crystals , Yield  54%; m.p. 113-115;FT IR (ʋ= cm-1,KBr): 3314 (OH str.), 3188  (NH str.) , 3117(NH str.) ,  3077 (Ar-
H str.) 2920 and 2872 (Asym.and sym. Str. of CH2), 1680 (C=O str. of amide), 1596 (C=N str.).
 1
HNMR(400MHz),(DMSO-
d6,δppm):12 (s,1H,-OH),11.8(s,1H,CO-NH-Ar), 11.4(s,1H,CO-NH),11.1 (s,1H,OH-NH),7-8.(m,4H,Ar-
H),4.2(s,2H,CH2S),3.6(t,2H,CH2-CO),2.7(t,4H,-CH2-) ; Elemental analysis Calcd for C16H18BrN5O4S2:C, 39.35; H, 3.71; N, 
14.34. Found: C, 39.87; H, 3.45; N, 14.09 
Synthesis of N1-hydroxy-N6-(5-(2-(4-methoxyphenylamino)-2-oxoethylthio)-1,3,4-thiadiazol-2-
yl)adipamide ,compound (5g). 
white crystals , Yield  65%; m.p. 133-136;FT IR (ʋ= cm-1,KBr): 3292 (OH str.), 3140  (NH str.) ,  3045 (Ar-H str.) 2935 and 
2875 (Asym.and sym. Str. of CH2), 1691 (C=O str. of amide), 1604 (C=N str.).
 1
HNMR(400MHz),(DMSO-d6,δppm):11.8 
(s,1H,-OH),11.4 (s,1H,CO-NH-Ar), 11.1(s,1H,CO-NH),10.7 (s,1H,OH-NH), 7-8. (m,4H,Ar-H),4.3(s,2H,CH2-S),3.8 (t, 
2H,CH2-CO),3.4(s,3H,CH3-O),2.3(t,4H,-CH2-) ; Elemental analysis Calcd for C17H21N5O5S2:C, 46.46; H, 3.71; N, 15.93. 
Found: C, 39.87; H, 3.45; N, 14.09 
CYTOTOXICITY ASSAY (MTT ASSAY((17)(18)(19). 
MTT cell viability assay was conducted on 96-well plates (Santacruz Biotechnology, USA), Hela and Normal Embryonic 
cells were seeded at 10000 cells/well, 200 μl of cells in growth medium were added to each well of a sterile 96-well 
microtitration plate. The plates were sealed with a self-adhesive film, lid placed on and incubated at 37°C.After 24hr or 
confluent monolayer is achieved, when the cells were in exponential growth, the medium was removed and serial dilutions 
of the compounds(5a,5c,5e and 5f) were added to the wells. triplicates were used for each. Control cells treated with 
Serum Free Media only as well as positive control treated with the solvent (DMSO) in the same concentration used to 
solve the chemical compounds. Afterwards, the plates were re-incubated at 37°C for 72 hrs. 
Cell viability was measured after 72 hrs of exposure by removing the medium, adding 28 µl of 2 mg/ml solution of MTT 
(Bio-World, USA) and incubating for 1.5h at 37°C. After removing the MTT solution, the crystals remaining in the wells 
were solubilised by the addition of 130 µl of DMSO (Dimethyl Sulphoxide) (Santacruz Biotechnology, USA) followed by 
37°C incubation for 15 min with shaking. 
The absorbency was determined on a microplate reader (Biochrom, UK) at 584 nm (test wavelength); the assay was 
performed intriplicate. 
3.RESULTS AND DISCUSSION 
3.1 Chemistry 
       The synthesis of the title compounds (1), (2a-f) and (3a-g) to( 5a-g) was accomplished anddepicted  in the scheme 
1,The scheme1 illustrated the reactions steps  for all synthesized derivatives.in which compound 1 was synthesized from 
the reaction of thiosemicarbazide with CS2 in the presence of sodium carbonate.while each of compounds 2a-f were 
synthesized from the reaction of CAC with benzyl amine , 2-aminopyridine ,(p-nitro,p-chloro ,p-bromo and p-methoxy 
anile). 
The synthesis of compounds 3a-g were done by alkylation of thiolate ion of compound 1 in aqueous media(green 
reactions).Compounds 4a-g were synthesized by activation of carboxyl group of adipic acid mono ethyl ester by thionyl 
chloride and reaction of the produced acid chloride with amine in dry conditions with presence of TEA to neutralizes the 
acid  produced during the reaction. 
The compounds 5a-g were synthesized by aminolysis of ester group in compounds 4a-g by hydroxyl amine in alcoholic 
solution with the presence of KCN as a catalyst. 
The IR spectrum of compound 1 shows the appearance of characteristics bands such as asymmetric and symmetric 
stretching of amine and also the appearance of absorption band in about 2500-2700 which represent SH stretching. The 
IR spectrum of (2a-f) show disappearance of asymmetric and symmetric stretching for primary aromatic NH2 in the starting 
compounds and  the appearance of new absorption bands which represent  the  NH stretching of secondary amide and 
C=O stretching vibration of amide (amide I Band) respectively , at (2278 ,1651) for compound 2a , at (3251 ,1681 ) for 2b, 
at (3228 , 1685 ) for 2c ,  at ( 3282 ,1652 ) for 2d  at (3263 ,1668 ) for 2e and at (3294 , 1669) for 2f. 
The IR spectra of( 3a-g) show disappearance of the absorption band of SH  group in compound 1 at 2773  and the 
appearance of weak bands in some of the synthesized compound which represents C-S-C   stretching vibration that don’t 
has structural diagnostic value., in addition to the appearance of strong bands of asymmetric and symmetric stretching 
vibration of NH2 of thiazole ring and the strong bands of C=O stretching of amide bands in the synthesized compounds . 
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The IR spectrum (4a-g) shows disappearance of asymmetric and symmetric stretching of NH2 in the reactants and the 
appearance of new strong bands that represents  the C=O stretching vibration of ester at (1733) for 4a , at (1722) for 4b ,  
at (1734) for 4c , at (1728) for 4d, at(1732) for 4e ,at (1731) for 4f and at (1718) for 4g respectively . 
The IR spectra of (5a-g) shows the disappearance of C=O stretching vibrations of ester in the reactants and the 
appearance of new and relatively broad bands whichresults from hydroxyl group  and NH  group stretching vibration of 
hydroxamic acid respectively . These bands appears at ( 3338,3252 ) 5a , at (3292 overlapped ) for 5b , at (3280 
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Scheme(1): Synthesis of compounds (1),(2a-f) and(3a-g) to (5a-g). 
 
 
3.2 Cytotoxicity evaluation 
MTT cell viability assay was performed on both Hela nuclear extract and Normal Embryonic cells, to determine the 
preliminary antitumor activities and safety indexes for  some of the synthesized compounds, the results of the tested 
compounds 5a,5c,5e and 5fshows that , these compounds have good cytotoxic activity and also good selectivityfor cancer 
cellswhich represented by their high inhibition rate of cancer cells viability with low inhibition rate on normal cells, 





















Figure 1 :Comparative Study for the cytotoxic effect of compounds (5a ,5c ,5e,5f)    on HeLa and Normal 
embryonic cells for studying the safety index. . 
CONCLUSION 
In this work, we report the synthesis of new derivatives of hydroxamic acid based- HDACis containing substituted 1,3,4 
thiadiazole as a surface recognition moieties with aliphatic linker, and evaluated for their antitumor activities against both 
HeLa nuclear extract cell lines and normal emberoinic fibroblast cells. Some of the tested compounds have good 
antitumor activities represented by inhibition of cell viability, while have no or little effects on normal cells as demonstrated 
by high safety index especially compounds 5a and 5e that show the highest  tumor cell selectivity. 
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